ENG
ESP
Recommendation of the Advisory Committee on Vaccines and Immunization Strategies on monkeypox vaccination in Chile
Published 2023-01-26
Keywords
How to Cite
Copyright (c) 2023 Vivian Luchsinger, Jeannette Dabanch, Alejandra King, Jan Wilhelm, Adiela Saldaña, María Paz Bertoglia, Christian García, María L. Endeiza, Jaime Rodríguez
This work is licensed under a Creative Commons Attribution 4.0 International License.
Abstract
Monkeypox was declared a public health emergency of international concern by the World Health Organization during 2022. In Chile, over 450 patients have been confirmed until September, mostly young men.
This zoonotic poxvirus is transmitted from humans to humans through close contact; it is a self-limiting disease and can be fatal in people with immunodeficiency.
Prevention by immunization is important. MVA-BN, one of the three vaccines available, it is a third generation vaccine, based on non-replicating modified vaccinia virus, therefore can be administered to immunocompromised patients and pregnant women and it has been approved for monkeypox in people over 18 years of age. The available information on efficacy and effectiveness is limited.
The CAVEI recommends incorporating this vaccine to interrupt the chain of transmission and reduce the risk of severe disease, administered subcutaneously in two doses, 28 days apart, prioritizing post exposure use for close contacts of confirmed cases with risk of severe disease, ideally within 4 days of exposure and it can be used up to 14 days after exposure and in the absence of symptoms.
When the vaccine supply allows it, its application is recommended as pre-exposure prevention for people with high-risk sexual practices or with occupational risk. This recommendation could be modified according to epidemiology, vaccines supply and new scientific information.